Navigation Links
FDA Approves PREZISTA®/ritonavir Once-Daily Dosing for HIV-1 Treatment-Experienced Adults With No Darunavir Resistance-Associated Mutations
Date:12/13/2010

olytic hepatitis) has been reported with PREZISTA/ritonavir. During the clinical development program (N=3063), hepatitis has been reported in 0.5% of patients receiving combination therapy with PREZISTA/ritonavir. Patients with preexisting liver dysfunction, including chronic active hepatitis B or C, have an increased risk for liver function abnormalities, including severe hepatic adverse events

Post-marketing cases of liver injury, including some fatalities, have been reported. A causal relationship with PREZISTA/ritonavir therapy has not been establishedAppropriate laboratory testing should be conducted prior to initiating therapy with PREZISTA/ritonavir and patients should be monitored during treatment. Increased AST/ALT monitoring should be considered in patients with underlying chronic hepatitis, cirrhosis, or in patients who have pretreatment elevations of transaminases, especially during the first several months of PREZISTA/ritonavir treatment. Evidence of new or worsening liver dysfunction (including clinically significant elevation of liver enzymes and/or symptoms such as fatigue, anorexia, nausea, jaundice, dark urine, liver tenderness, hepatomegaly) in patients on PREZISTA/ritonavir should prompt consideration of interruption or discontinuation of treatment


  • Severe Skin Reactions:  Severe skin reactions (0.4%), accompanied by fever and/or elevations of transaminases in some cases, Stevens-Johnson Syndrome (<0.1%), and toxic epidermal necrolysis (post-marketing experience) have been reported in patients receiving PREZISTA/ritonavir.  Discontinue PREZISTA/ritonavir immediately if signs or symptoms of severe skin reactions develop (including, but not limited to, severe rash or rash accompanied with fever, general malaise, fatigue, muscle or join aches, blisters, oral lesions, conjunctivitis, hepatitis and/or eosinophilia)  

  • In clinical trials (N=3063), rash (all grades, generally m
    '/>"/>

    SOURCE Tibotec Therapeutics
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
    2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
    3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
    4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
    5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
    6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
    7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
    8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
    9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
    10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
    11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/30/2014)... ATLANTA , Sept. 30, 2014  Georgia-Pacific ... systems, towels and tissue for a wide range ... success of its product lines in healthcare, including ... practices, Georgia-Pacific Professional is introducing its healthcare products ... "Georgia-Pacific Professional understands the importance of infection control ...
    (Date:9/30/2014)... 30, 2014   Decision Resources Group finds ... anemic chronic kidney disease non-dialysis (CKD-ND) patients are ... medication. In addition, one-year persistency is similar between ... Other key findings from the report entitled ... Erythropoiesis Stimulating Agents in Late Stage Chronic Kidney ...
    (Date:9/30/2014)... , Sept. 30, 2014   Acutus ... minimally invasive real-time 3D Cardiac Chamber Imaging and Dipole ... and / or sustain complex cardiac arrhythmias, including atrial ... to continue developing its imaging/mapping system as well as ... will allow Acutus Medical to complete work on the ...
    Breaking Medicine Technology:Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 2Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 3Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 2Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 3
    ... NEW YORK, Oct. 7 Reportlinker.com announces that ... its catalogue: U.S. Venous Access ... This study covers U.S. markets for ... (PICCs), central venous catheters (CVCs), dialysis catheters, implantable ...
    ... Halozyme Therapeutics, Inc. (Nasdaq: HALO ), ... extracellular matrix, today announced that it will host a ... in New York. During the meeting, Halozyme,s management will ... business alliances with Roche and Baxter, and an update ...
    Cached Medicine Technology:Reportlinker Adds U.S. Venous Access Catheter Market 2Reportlinker Adds U.S. Venous Access Catheter Market 3Reportlinker Adds U.S. Venous Access Catheter Market 4Halozyme Therapeutics to Host Analyst Meeting on October 14 in New York 2
    (Date:9/30/2014)... no genetic evidence that high levels of vitamin D ... Some previous research had suggested that elevated levels ... diabetes, raising the possibility of a link between vitamin ... this study, British researchers investigated the association between diabetes ... control blood levels of vitamin D. They found no ...
    (Date:9/30/2014)... 2014 (HealthDay News) -- Children conceived either less than one ... a sibling could be at increased risk for autism, a ... and an outside expert agree that the research can,t prove ... "Most importantly, it is important that parents understand that the ... are close together or far apart," said outside expert Dr. ...
    (Date:9/30/2014)... to cut climate-changing carbon emissions will reduce other ... benefits, according to a new study released today. ... options included in the final Clean Power Plan, ... premature deaths and hospitalizations, and hundreds of heart ... the new study, Health Co-benefits of Carbon Standards ...
    (Date:9/30/2014)... By Alan Mozes ... 2014 (HealthDay News) -- Colon cancer patients who are ... slightly higher risk for developing a second weight-related cancer, ... to the risk of colon cancer recurrence, only the ... , "We found that colorectal cancer survivors who reported ...
    (Date:9/30/2014)... lung cancer, breast cancer is the leading cause of ... Society. That,s why so many medical professionals encourage women ... at best: only a minority of suspicious mammograms actually ... lots of needless worry for women and their familiesnot ... tests, including ultrasounds and biopsies. , Recently, a ...
    Breaking Medicine News(10 mins):Health News:Gene Study Finds No Proof Vitamin D Guards Against Type 2 Diabetes 2Health News:Spacing Between Sibling Births Tied to Autism Risk in Study 2Health News:Power plant standards could save thousands of US lives every year 2Health News:Power plant standards could save thousands of US lives every year 3Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 2Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 3Health News:'Virtual breast' could improve cancer detection 2
    ... BOZEMAN, Mont. -- West Nile virus is apparently here to ... entomologist Greg Johnson. , Urging Montanans to protect themselves with ... sure to emerge when temperatures reach the 70s and 80s. ... as they were in 2003 and 2007, but Montanans should ...
    ... brain, study reports , , WEDNESDAY, June 11 (HealthDay ... risk of experiencing a stroke in which there is bleeding ... , Researchers, reviewing the medical records of almost 30,000 people ... ran nearly twice the risk of a subarachnoid hemorrhage than ...
    ... Researchers from the Case Western Reserve University School of ... a novel therapeutic that reduces sterile inflammation within the ... Journal of Leukocyte Biology, Dr. Eric Pearlman and ... compound that when delivered in nano-sized packages reduces corneal ...
    ... Efficiency in Health Care has assessed recent evidence on allergies. ... symptoms can definitely help many people with allergies. , When ... season has hit its peak. And the number of people ... in get hayfever, and up to half of the population ...
    ... be quizzed about their children,s sex education in a unique ... taught to deaf pupils. , The University of Manchester,s Audiology ... hearing primary school children for its research on children,s sex ... will make SRE more accessible for deaf children and, at ...
    ... NEW YORK, June 11 WallSt.net,s 3-Minute Press Show ... Tolentino., Shows air Monday through Friday on: ... interviews with,public company executives on their company and most ... with insight into a company,s most,recent press release, and ...
    Cached Medicine News:Health News:Wet or dry, Montana still threatened by West Nile 2Health News:Women, Mexican Americans at Higher Risk for Certain Stroke 2Health News:Latest research on allergies: Specific immunotherapy can help 2Health News:Study aims to improve sex education for deaf pupils 2Health News:Study aims to improve sex education for deaf pupils 3Health News:[video] WallSt.net's '3 Minute Press Show' Features Executive Interviews and Highlights Recent Press for the Following: IUSA, IFUE, FEED, RXEI, GMPM, CRCUF, CVSC, GNMT 2Health News:[video] WallSt.net's '3 Minute Press Show' Features Executive Interviews and Highlights Recent Press for the Following: IUSA, IFUE, FEED, RXEI, GMPM, CRCUF, CVSC, GNMT 3
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    Medicine Products: